Dendreon's Provenge Recommended by European committee

New article posted at Seeking Alpha:

Dendreon Gets European Recommendation

See also my: Q1 2013 Dendreon Analyst Conference Notes

Provenge is approved in the United States for the treatment of metastatic minimally symptomatic castrate-resistant prostate cancer. Dendreon is seeking approval for Provenge in Europe.

Bought More Celgene (CELG)

In the interest of full disclosure, this is a note that I bought Celgene stock today at $111.40.

I had sold 17% of my CELG on June 7, 2013 for $126.80. Today I bought twice as much as I sold on June 7. Celgene is now the largest position by value in my portfolio.

I acquired my long Celgene position over time as follows:

6/7/2007 at $59.34
5/4/2009 at $38.59
1/28/2011 at $52.40

For my latest analysis of Celgene see:

Celgene 2013 Guidance: Two Times 2013 Revenue

Note that while I like and own Celgene, my portfolio is constructed to balance risks and opportunities as a whole.

Keep diverfied!

Red Hat (RHT) Q1 2013 results and conference notes

Despite being on vacation, I took notes on the Red Hat conference:

RHT (Red Hat) analyst conference notes, Q1 2013

Adobe Fiscal Q2 2013 Analyst Conference Notes

My notes on the latest Adobe (ADBE) results and conference can be found here:

Adobe Fiscal Q2 2013 Analyst Conference Notes

It is still hard to tell at this point how the shift to selling Adobe prodocts as subscriptions rather than in iterations (CS6 following CS5, etc.) by download or disks will work out. Revenues are not climbing, and profits are down, but this was expected even if the shift to subscriptions is successful. Management sounds confident, and seem to be executing to plan. No money down, pay later plans are the American dream, so it will likely work out but for investors it is a waiting game.

New post on Inovio (INO)

Yesterday I was thinking I had not written about Inovio (INO)  for some time. I checked Seeking Alpha to make sure no one was writing about the company, and too my surprise found several articles already there.

One negative article struck me as mistaken in its analysis. I like to read negative articles because too often the negative points of stocks are ignored. But I did a bit of research and concluded that, while nothing guarantees that a small company like Inovio will ever get FDA clearance for its vaccines, Inovio is still a buy for me.

Here's the article: Sorting Out Inovio Claims

Once again, this is not a recommendation for anyone to buy INO. It is a high-risk biotechnology stock and should only be owned by people who know how to manage such risks properly.

Keep diversified!

Cantel Medical (CMN) outlook

My latest at Seeking Alpha

Cantel Medical (CMN) April quarter results and outlook [June 9, 2013]

Cantel Medical over the last 5 years has proven to have sound management. Growth prospects now appear to be as good as ever. The infection control market is growing because of the increase in global pandemics and antibiotic-resistant bacteria. This is not a hot short-term trade, but as a long-term investment I can highly recommend it.

You can also read my detailed notes on the analyst call: 

Cantel Medical Fiscal Q3 2013 analyst call notes

Cantel Medical Analyst Call (CMN)

I have posted my notes on today's Cantel Medical (CMN) analyst conference call here:

Cantel Medical fiscal third quarter 2013

Cantel had a good, but not spectacular, quarter.

I own stock in CMN. I have watched them expand revenue in the healthcare infection-prevention market for several years now. I see no reason Cantel should not continue to do well these next few years and see a gradual but significant rise in the stock price.

I hope to post a longer analysis at Seeking Alpha sometime today or tormorrow.

Microchip (MCHP) Increases Guidance

My newest article at Seeking Alpha:

Microchip Ups Guidance

I should add that I first bought Microchip (MCHP) stock in 2006 and it has always been reliable, even during the recession. Management is as honest as they come, though of course on occasion events occur that they could not foresee.

I became aware of Microchip from playing with microcontrollers when I thought I might make a hobby of robotics. I used a STAMP board, which was set up with a working PIC microcontroller. It was amazing how easy it was to write small programs to turn electronic devices on and off and monitor the environment.